Please login to the form below

Not currently logged in
Email:
Password:

Lilly names Plowman as oncology research chief

Eli Lilly has selected Greg Plowman, formerly senior director at Roche Group's Genentech, to lead its oncology research efforts

Eli Lilly and Company has appointed Greg Plowman as the vice president, oncology research and senior vice president of ImClone Systems research.

Plowman will oversee the oncology research efforts of Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's Alexandria Center for Life Science in New York City, US.

Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group. He has 25 years of experience in cancer research including leadership roles at Oncogene, Sugen, Exelixis and Genentech, which became part of Bristol-Myers Squibb, Pharmacia and Roche.

Lilly acquired ImClone in 2008, broadening its portfolio and strengthening its oncology pipeline and biotech capabilities. The company has one of the largest clinical-stage pipelines of potential cancer medicines in the industry with more than 30 molecules.

 

10th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics